<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Drug 1</th>
      <th>Drug 2</th>
      <th>Interaction Type</th>
      <th>Clinical Significance</th>
      <th>Management</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Fluconazole</td>
      <td>Clarithromycin</td>
      <td>Increased levels of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Codeine</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Midazolam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Amoxicillin</td>
      <td>Risperidone</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Amiodarone</td>
      <td>Hyperkalemia</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Verapamil</td>
      <td>Risk of QT prolongation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Fluoxetine</td>
      <td>Hydrochlorothiazide</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Amiodarone</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Tacrolimus</td>
      <td>Cyclosporine</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Clinical monitoring is essential.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Codeine</td>
      <td>Ciclosporin</td>
      <td>Potentially dangerous interaction</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Erythromycin</td>
      <td>Increased sedation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Codeine</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Topiramate</td>
      <td>Increased risk of arrhythmias</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Oxycodone</td>
      <td>Increased sedation</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Methadone</td>
      <td>Increased sedation</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Tacrolimus</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Quetiapine</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Alprazolam</td>
      <td>Increased levels of Drug 1</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Ondansetron</td>
      <td>Risk of QT prolongation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Clarithromycin</td>
      <td>Risk of QT prolongation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Tramadol</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Clinical monitoring is essential.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>Olanzapine</td>
      <td>Risk of QT prolongation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Codeine</td>
      <td>Increased levels of Drug 1</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Hydrocodone</td>
      <td>Hyperkalemia</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Pregabalin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Methotrexate</td>
      <td>Amoxicillin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Clinical monitoring is essential.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Ibuprofen</td>
      <td>Increased levels of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Methotrexate</td>
      <td>Amoxicillin</td>
      <td>Increased sedation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Clarithromycin</td>
      <td>Increased sedation</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Levothyroxine</td>
      <td>Risk of severe hypotension</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Diltiazem</td>
      <td>Tramadol</td>
      <td>Hyperkalemia</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Cyclosporine</td>
      <td>Metoclopramide</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Midazolam</td>
      <td>Rifampin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Alprazolam</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Azithromycin</td>
      <td>Risk of QT prolongation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Fluconazole</td>
      <td>Paracetamol</td>
      <td>Risk of renal impairment</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Paracetamol</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Aspirin</td>
      <td>Risk of severe hypotension</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Lorazepam</td>
      <td>Increased risk of side effects</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Aspirin</td>
      <td>Increased levels of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Codeine</td>
      <td>Diazepam</td>
      <td>Increased sedation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>ACE Inhibitors</td>
      <td>Clonazepam</td>
      <td>Risk of severe hypotension</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Tramadol</td>
      <td>Increased risk of arrhythmias</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Warfarin</td>
      <td>Pregabalin</td>
      <td>Serotonin syndrome</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Cyclosporine</td>
      <td>Olanzapine</td>
      <td>Increased risk of arrhythmias</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lamotrigine</td>
      <td>Levothyroxine</td>
      <td>Increased levels of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Sertraline</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Azithromycin</td>
      <td>Risk of QT prolongation</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Prednisone</td>
      <td>Risk of QT prolongation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Fluoxetine</td>
      <td>Risk of renal impairment</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Codeine</td>
      <td>Losartan</td>
      <td>Increased risk of arrhythmias</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Aripiprazole</td>
      <td>Hydrochlorothiazide</td>
      <td>Risk of severe hypotension</td>
      <td>Avoid concurrent use if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Clarithromycin</td>
      <td>Valproate</td>
      <td>Increased levels of Drug 1</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Midazolam</td>
      <td>Increased levels of Drug 1</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Metformin</td>
      <td>Tacrolimus</td>
      <td>Hyperkalemia</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Prednisone</td>
      <td>Tacrolimus</td>
      <td>Risk of QT prolongation</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Morphine</td>
      <td>Metformin</td>
      <td>Risk of severe hypotension</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Itraconazole</td>
      <td>Increased bleeding risk</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Warfarin</td>
      <td>Risk of severe hypotension</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Citalopram</td>
      <td>Increased sedation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Risperidone</td>
      <td>Atorvastatin</td>
      <td>Risk of QT prolongation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Azithromycin</td>
      <td>Ciclosporin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Clinical monitoring is essential.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Lamotrigine</td>
      <td>Hyperkalemia</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Aspirin</td>
      <td>Risk of renal impairment</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Midazolam</td>
      <td>Clarithromycin</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Azithromycin</td>
      <td>Clarithromycin</td>
      <td>Increased risk of side effects</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Pregabalin</td>
      <td>Simvastatin</td>
      <td>Increased risk of side effects</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Ondansetron</td>
      <td>Risk of severe hypotension</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Haloperidol</td>
      <td>Risk of severe hypotension</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Ibuprofen</td>
      <td>Phenytoin</td>
      <td>Risk of QT prolongation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Losartan</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Metoclopramide</td>
      <td>Carbamazepine</td>
      <td>Increased risk of arrhythmias</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Erythromycin</td>
      <td>Metformin</td>
      <td>Increased bleeding risk</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Dexamethasone</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Paracetamol</td>
      <td>Simvastatin</td>
      <td>Hyperkalemia</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Tacrolimus</td>
      <td>Serotonin syndrome</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Methotrexate</td>
      <td>Increased sedation</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Codeine</td>
      <td>Amiodarone</td>
      <td>Risk of renal impairment</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>ACE Inhibitors</td>
      <td>Hydrochlorothiazide</td>
      <td>Increased bleeding risk</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Alprazolam</td>
      <td>Risk of renal impairment</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Morphine</td>
      <td>Levothyroxine</td>
      <td>Risk of QT prolongation</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Erythromycin</td>
      <td>Omeprazole</td>
      <td>Hyperkalemia</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Methadone</td>
      <td>Increased sedation</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Metformin</td>
      <td>Fentanyl</td>
      <td>Increased risk of side effects</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Amiodarone</td>
      <td>Increased sedation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Azithromycin</td>
      <td>Gabapentin</td>
      <td>Serotonin syndrome</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Amoxicillin</td>
      <td>Ibuprofen</td>
      <td>Serotonin syndrome</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Amoxicillin</td>
      <td>Increased sedation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>ACE Inhibitors</td>
      <td>Increased risk of arrhythmias</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Midazolam</td>
      <td>Risk of severe hypotension</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Metformin</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Amoxicillin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Warfarin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Dexamethasone</td>
      <td>Furosemide</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Alprazolam</td>
      <td>Hyperkalemia</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Spironolactone</td>
      <td>Increased bleeding risk</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Prednisone</td>
      <td>Potentially dangerous interaction</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Fluconazole</td>
      <td>Serotonin syndrome</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Metoclopramide</td>
      <td>Increased sedation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Fluconazole</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Aspirin</td>
      <td>Potentially dangerous interaction</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Oxycodone</td>
      <td>Increased bleeding risk</td>
      <td>Clinical monitoring is essential.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Clarithromycin</td>
      <td>Prednisone</td>
      <td>Increased levels of Drug 1</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Lorazepam</td>
      <td>Increased risk of side effects</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Midazolam</td>
      <td>Valproate</td>
      <td>Increased risk of side effects</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Aspirin</td>
      <td>Increased bleeding risk</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Gabapentin</td>
      <td>Increased sedation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Haloperidol</td>
      <td>Prednisone</td>
      <td>Increased risk of arrhythmias</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Ketoconazole</td>
      <td>Levothyroxine</td>
      <td>Serotonin syndrome</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Tramadol</td>
      <td>Levothyroxine</td>
      <td>Risk of severe hypotension</td>
      <td>Clinical monitoring is essential.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Cyclosporine</td>
      <td>Risk of severe hypotension</td>
      <td>Clinical monitoring is essential.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Aspirin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Amoxicillin</td>
      <td>Hyperkalemia</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Topiramate</td>
      <td>Increased risk of arrhythmias</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Rifampin</td>
      <td>Methadone</td>
      <td>Increased bleeding risk</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Fluoxetine</td>
      <td>Risk of severe hypotension</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Morphine</td>
      <td>Lorazepam</td>
      <td>Increased risk of side effects</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Rifampin</td>
      <td>Methadone</td>
      <td>Increased levels of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Ondansetron</td>
      <td>Hyperkalemia</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Erythromycin</td>
      <td>Fluconazole</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Risperidone</td>
      <td>Paracetamol</td>
      <td>Hyperkalemia</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Diltiazem</td>
      <td>Hydrochlorothiazide</td>
      <td>Potentially dangerous interaction</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Risperidone</td>
      <td>Pregabalin</td>
      <td>Increased risk of side effects</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Aripiprazole</td>
      <td>Verapamil</td>
      <td>Serotonin syndrome</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Carbamazepine</td>
      <td>Digoxin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Metformin</td>
      <td>Lamotrigine</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Amiodarone</td>
      <td>Serotonin syndrome</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Aripiprazole</td>
      <td>Diazepam</td>
      <td>Risk of severe hypotension</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Dexamethasone</td>
      <td>Lithium</td>
      <td>Increased sedation</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Pregabalin</td>
      <td>Ciclosporin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Prednisone</td>
      <td>Atorvastatin</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>Paracetamol</td>
      <td>Serotonin syndrome</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Quetiapine</td>
      <td>Serotonin syndrome</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Fluconazole</td>
      <td>Codeine</td>
      <td>Increased sedation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Ciclosporin</td>
      <td>Furosemide</td>
      <td>Hyperkalemia</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Aripiprazole</td>
      <td>Risperidone</td>
      <td>Hyperkalemia</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Furosemide</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Tacrolimus</td>
      <td>Lisinopril</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Carbamazepine</td>
      <td>Serotonin syndrome</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lorazepam</td>
      <td>Erythromycin</td>
      <td>Risk of severe hypotension</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Morphine</td>
      <td>Alprazolam</td>
      <td>Increased risk of side effects</td>
      <td>Clinical monitoring is essential.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Warfarin</td>
      <td>Verapamil</td>
      <td>Increased risk of arrhythmias</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Hydrochlorothiazide</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Tacrolimus</td>
      <td>Ketoconazole</td>
      <td>Risk of severe hypotension</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Spironolactone</td>
      <td>Increased sedation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Verapamil</td>
      <td>Midazolam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Dexamethasone</td>
      <td>Tacrolimus</td>
      <td>Risk of QT prolongation</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Valproate</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Valproate</td>
      <td>Citalopram</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Clozapine</td>
      <td>Amoxicillin</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Warfarin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Carbamazepine</td>
      <td>Tacrolimus</td>
      <td>Increased levels of Drug 1</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Citalopram</td>
      <td>Increased sedation</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Verapamil</td>
      <td>Potentially dangerous interaction</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Paracetamol</td>
      <td>Methadone</td>
      <td>Increased bleeding risk</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Itraconazole</td>
      <td>Potentially dangerous interaction</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Losartan</td>
      <td>Increased risk of side effects</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Clozapine</td>
      <td>Serotonin syndrome</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Ciclosporin</td>
      <td>Clozapine</td>
      <td>Increased sedation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Hydrochlorothiazide</td>
      <td>Risk of QT prolongation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Prednisone</td>
      <td>Metoclopramide</td>
      <td>Serotonin syndrome</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Lorazepam</td>
      <td>Increased bleeding risk</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Paracetamol</td>
      <td>Lithium</td>
      <td>Increased risk of arrhythmias</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Cyclosporine</td>
      <td>Risk of QT prolongation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Fluoxetine</td>
      <td>Haloperidol</td>
      <td>Risk of severe hypotension</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Clozapine</td>
      <td>Azithromycin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Methadone</td>
      <td>Rifampin</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Clinical monitoring is essential.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Codeine</td>
      <td>Risk of QT prolongation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Tramadol</td>
      <td>Diazepam</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Fluoxetine</td>
      <td>Risk of severe hypotension</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Lorazepam</td>
      <td>Increased levels of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Alprazolam</td>
      <td>Increased risk of side effects</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Prednisone</td>
      <td>Atorvastatin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Codeine</td>
      <td>Risk of severe hypotension</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Erythromycin</td>
      <td>Serotonin syndrome</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Methotrexate</td>
      <td>ACE Inhibitors</td>
      <td>Increased bleeding risk</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Furosemide</td>
      <td>Risk of renal impairment</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Omeprazole</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>Furosemide</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Hydrocodone</td>
      <td>Hyperkalemia</td>
      <td>Clinical monitoring is essential.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Dexamethasone</td>
      <td>Fentanyl</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Erythromycin</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Risperidone</td>
      <td>Increased sedation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Ciclosporin</td>
      <td>Serotonin syndrome</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Azithromycin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Tamoxifen</td>
      <td>Increased risk of side effects</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Spironolactone</td>
      <td>Risk of renal impairment</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>Prednisone</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Tramadol</td>
      <td>Clonazepam</td>
      <td>Increased risk of arrhythmias</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Haloperidol</td>
      <td>Ketoconazole</td>
      <td>Increased bleeding risk</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Tramadol</td>
      <td>Increased bleeding risk</td>
      <td>Avoid concurrent use if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Clonazepam</td>
      <td>Serotonin syndrome</td>
      <td>Clinical monitoring is essential.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Ketoconazole</td>
      <td>Erythromycin</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Gabapentin</td>
      <td>Potentially dangerous interaction</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>ACE Inhibitors</td>
      <td>Increased bleeding risk</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Spironolactone</td>
      <td>Methotrexate</td>
      <td>Serotonin syndrome</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Warfarin</td>
      <td>Potentially dangerous interaction</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Metoclopramide</td>
      <td>Lisinopril</td>
      <td>Increased sedation</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>Gabapentin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Midazolam</td>
      <td>Diazepam</td>
      <td>Risk of renal impairment</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Clonazepam</td>
      <td>Fluconazole</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Pregabalin</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Hydrocodone</td>
      <td>Alprazolam</td>
      <td>Risk of severe hypotension</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Lisinopril</td>
      <td>Increased risk of arrhythmias</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Tamoxifen</td>
      <td>Increased bleeding risk</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Sertraline</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Hydrocodone</td>
      <td>Tamoxifen</td>
      <td>Increased levels of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Prednisone</td>
      <td>Paracetamol</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Clinical monitoring is essential.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Omeprazole</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>Digoxin</td>
      <td>Decreased absorption of Drug 1</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Aspirin</td>
      <td>Increased levels of Drug 1</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Metoclopramide</td>
      <td>Erythromycin</td>
      <td>Hyperkalemia</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Gabapentin</td>
      <td>Amiodarone</td>
      <td>Increased levels of Drug 1</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Clozapine</td>
      <td>Increased bleeding risk</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Midazolam</td>
      <td>Serotonin syndrome</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Itraconazole</td>
      <td>Carbamazepine</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Erythromycin</td>
      <td>Simvastatin</td>
      <td>Risk of severe hypotension</td>
      <td>Clinical monitoring is essential.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Diltiazem</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Fluconazole</td>
      <td>Potentially dangerous interaction</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Rifampin</td>
      <td>Sertraline</td>
      <td>Increased levels of Drug 1</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>Citalopram</td>
      <td>Increased bleeding risk</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Omeprazole</td>
      <td>Increased risk of side effects</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lithium</td>
      <td>Levothyroxine</td>
      <td>Risk of severe hypotension</td>
      <td>Clinical monitoring is essential.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Valproate</td>
      <td>Warfarin</td>
      <td>Increased risk of side effects</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Gabapentin</td>
      <td>Itraconazole</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Pregabalin</td>
      <td>Risk of renal impairment</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Clozapine</td>
      <td>Risk of QT prolongation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Spironolactone</td>
      <td>Olanzapine</td>
      <td>Increased bleeding risk</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Risperidone</td>
      <td>Midazolam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Lithium</td>
      <td>Risk of QT prolongation</td>
      <td>Clinical monitoring is essential.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Methotrexate</td>
      <td>Lithium</td>
      <td>Increased risk of side effects</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Losartan</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Ciclosporin</td>
      <td>Ondansetron</td>
      <td>Risk of renal impairment</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Diltiazem</td>
      <td>Increased risk of arrhythmias</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Quetiapine</td>
      <td>Clonazepam</td>
      <td>Risk of severe hypotension</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Sertraline</td>
      <td>Olanzapine</td>
      <td>Increased bleeding risk</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Ondansetron</td>
      <td>Hyperkalemia</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Paracetamol</td>
      <td>Losartan</td>
      <td>Increased bleeding risk</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Methadone</td>
      <td>Citalopram</td>
      <td>Risk of severe hypotension</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Omeprazole</td>
      <td>Increased sedation</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Metoclopramide</td>
      <td>Increased levels of Drug 1</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Atorvastatin</td>
      <td>Prednisone</td>
      <td>Increased risk of side effects</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Diltiazem</td>
      <td>Quetiapine</td>
      <td>Increased levels of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>ACE Inhibitors</td>
      <td>Morphine</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Valproate</td>
      <td>Methadone</td>
      <td>Potentially dangerous interaction</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Simvastatin</td>
      <td>Fluoxetine</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Lamotrigine</td>
      <td>Clarithromycin</td>
      <td>Risk of severe hypotension</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Topiramate</td>
      <td>Lorazepam</td>
      <td>Risk of renal impairment</td>
      <td>Clinical monitoring is essential.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Ibuprofen</td>
      <td>Lorazepam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Azithromycin</td>
      <td>Diazepam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Clinical monitoring is essential.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Rifampin</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Methadone</td>
      <td>Lithium</td>
      <td>Risk of severe hypotension</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>Omeprazole</td>
      <td>Increased levels of Drug 1</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Carbamazepine</td>
      <td>Increased bleeding risk</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Gabapentin</td>
      <td>Topiramate</td>
      <td>Increased sedation</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Verapamil</td>
      <td>Increased sedation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Carbamazepine</td>
      <td>Ketoconazole</td>
      <td>Serotonin syndrome</td>
      <td>Clinical monitoring is essential.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Citalopram</td>
      <td>Serotonin syndrome</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>Aspirin</td>
      <td>Increased risk of arrhythmias</td>
      <td>Clinical monitoring is essential.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Simvastatin</td>
      <td>Oxycodone</td>
      <td>Increased sedation</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Ketoconazole</td>
      <td>Hydrochlorothiazide</td>
      <td>Risk of renal impairment</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Metformin</td>
      <td>Serotonin syndrome</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
    <tr>
      <td>Fentanyl</td>
      <td>Azithromycin</td>
      <td>Decreased effectiveness of Drug 2</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Risperidone</td>
      <td>Losartan</td>
      <td>Risk of severe hypotension</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Carbamazepine</td>
      <td>Metformin</td>
      <td>Hyperkalemia</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Omeprazole</td>
      <td>Levothyroxine</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Azithromycin</td>
      <td>Increased sedation</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Gabapentin</td>
      <td>Methadone</td>
      <td>Serotonin syndrome</td>
      <td>Clinical monitoring is essential.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Methotrexate</td>
      <td>Aripiprazole</td>
      <td>Increased sedation</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Oxycodone</td>
      <td>Itraconazole</td>
      <td>Hyperkalemia</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>Erythromycin</td>
      <td>Risk of renal impairment</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>Quetiapine</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Patients should be counseled on potential risks.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Sertraline</td>
      <td>Risk of severe hypotension</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Carbamazepine</td>
      <td>Risk of renal impairment</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Alprazolam</td>
      <td>Levothyroxine</td>
      <td>Hyperkalemia</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Ketoconazole</td>
      <td>Lithium</td>
      <td>Increased risk of arrhythmias</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Olanzapine</td>
      <td>Aspirin</td>
      <td>Risk of renal impairment</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Citalopram</td>
      <td>Potentially dangerous interaction</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Clozapine</td>
      <td>Paracetamol</td>
      <td>Hyperkalemia</td>
      <td>May require dose adjustment or closer monitoring.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Hydrocodone</td>
      <td>Levothyroxine</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Spironolactone</td>
      <td>Lamotrigine</td>
      <td>Serotonin syndrome</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Alternative therapy should be considered if possible.</td>
    </tr>
    <tr>
      <td>Clozapine</td>
      <td>Simvastatin</td>
      <td>Risk of QT prolongation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Diazepam</td>
      <td>Tamoxifen</td>
      <td>Risk of renal impairment</td>
      <td>Increased monitoring of the patient is advised.</td>
      <td>Routine lab tests may be needed to monitor for effects.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Haloperidol</td>
      <td>Increased sedation</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Aspirin</td>
      <td>Hydrocodone</td>
      <td>Serotonin syndrome</td>
      <td>Clinical monitoring is essential.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Citalopram</td>
      <td>Omeprazole</td>
      <td>Increased sedation</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Ondansetron</td>
      <td>Topiramate</td>
      <td>Increased risk of side effects</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Haloperidol</td>
      <td>Clarithromycin</td>
      <td>Increased risk of side effects</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Levothyroxine</td>
      <td>Clonazepam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>Avoid concurrent use if possible.</td>
    </tr>
    <tr>
      <td>Fluconazole</td>
      <td>Codeine</td>
      <td>Increased levels of Drug 1</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Metoclopramide</td>
      <td>Amiodarone</td>
      <td>Risk of QT prolongation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Ketoconazole</td>
      <td>Sertraline</td>
      <td>Increased sedation</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Hydrochlorothiazide</td>
      <td>Gabapentin</td>
      <td>Risk of renal impairment</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Ciclosporin</td>
      <td>Azithromycin</td>
      <td>Increased bleeding risk</td>
      <td>Patients should be counseled on potential risks.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Tacrolimus</td>
      <td>Diazepam</td>
      <td>Increased levels of Drug 1</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
      <td>Increased monitoring of the patient is advised.</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>Diazepam</td>
      <td>Decreased absorption of Drug 1</td>
      <td>Combination should be avoided or used with caution.</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
    </tr>
    <tr>
      <td>Lithium</td>
      <td>Lamotrigine</td>
      <td>Potentially dangerous interaction</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>Combination should be avoided or used with caution.</td>
    </tr>
    <tr>
      <td>Rifampin</td>
      <td>Morphine</td>
      <td>Risk of renal impairment</td>
      <td>Avoid concurrent use if possible.</td>
      <td>Clinical monitoring is essential.</td>
    </tr>
    <tr>
      <td>Morphine</td>
      <td>Diazepam</td>
      <td>Risk of renal impairment</td>
      <td>Alternative therapy should be considered if possible.</td>
      <td>May require dose adjustment or closer monitoring.</td>
    </tr>
    <tr>
      <td>Tamoxifen</td>
      <td>Warfarin</td>
      <td>Decreased metabolism of Drug 2</td>
      <td>Consider drug interaction and adjust treatment accordingly.</td>
      <td>Monitor for signs of toxicity or adverse effects.</td>
    </tr>
  </tbody>
</table>